Kosh Agarwal

22.9k total citations · 6 hit papers
248 papers, 10.0k citations indexed

About

Kosh Agarwal is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Kosh Agarwal has authored 248 papers receiving a total of 10.0k indexed citations (citations by other indexed papers that have themselves been cited), including 211 papers in Hepatology, 183 papers in Epidemiology and 30 papers in Infectious Diseases. Recurrent topics in Kosh Agarwal's work include Hepatitis C virus research (172 papers), Liver Disease Diagnosis and Treatment (127 papers) and Hepatitis B Virus Studies (125 papers). Kosh Agarwal is often cited by papers focused on Hepatitis C virus research (172 papers), Liver Disease Diagnosis and Treatment (127 papers) and Hepatitis B Virus Studies (125 papers). Kosh Agarwal collaborates with scholars based in United Kingdom, United States and Italy. Kosh Agarwal's co-authors include Thomas Berg, Marı́a Buti, George Papatheodoridis, Pietro Lampertico, Harry L.A. Janssen, Fabien Zoulim, Frank Tacke, Graham R. Foster, Ivana Carey and Deepak Joshi and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Kosh Agarwal

227 papers receiving 9.8k citations

Hit Papers

EASL 2017 Clinical Practi... 2014 2026 2018 2022 2017 2014 2016 2019 2023 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
    2017 3.7k citations Pietro Lampertico, Kosh Agarwal et al. Journal of Hepatology profile →
  2. ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
    2014 646 citations Kosh Agarwal et al. profile →
  3. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
    2016 328 citations Graham R. Foster, William L. Irving et al. Journal of Hepatology profile →
  4. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
    2019 205 citations Kosh Agarwal, G. Mani Subramanian et al. Hepatology profile →
  5. EASL Clinical Practice Guidelines on hepatitis delta virus
    2023 112 citations Maurizia Rossana Brunetto, George Papatheodoridis et al. Journal of Hepatology profile →
  6. New Approaches to Chronic Hepatitis B
    2023 97 citations Geoffrey Dusheiko, Kosh Agarwal et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Kosh Agarwal 8.2k 8.2k 1.2k 788 423 248 10.0k
Pietro Andreoné 7.7k 0.9× 7.1k 0.9× 824 0.7× 1.3k 1.6× 662 1.6× 346 9.9k
Paul J. Pockros 6.5k 0.8× 6.2k 0.8× 1.1k 0.9× 580 0.7× 395 0.9× 190 8.5k
Marion G. Peters 7.0k 0.8× 7.0k 0.9× 1.4k 1.2× 1.0k 1.3× 1.1k 2.6× 211 9.9k
Robert P. Perrillo 8.4k 1.0× 8.9k 1.1× 1.0k 0.8× 469 0.6× 366 0.9× 119 10.1k
Ramsey Cheung 4.4k 0.5× 5.5k 0.7× 634 0.5× 678 0.9× 460 1.1× 211 7.4k
Vinod K. Rustgi 11.9k 1.4× 10.7k 1.3× 1.6k 1.3× 690 0.9× 592 1.4× 173 13.8k
Lennox J. Jeffers 6.4k 0.8× 6.4k 0.8× 738 0.6× 1.1k 1.4× 176 0.4× 136 8.3k
Wan‐Long Chuang 8.5k 1.0× 8.3k 1.0× 733 0.6× 732 0.9× 553 1.3× 513 11.1k
Douglas T. Dieterich 6.9k 0.8× 7.0k 0.9× 2.3k 1.9× 359 0.5× 220 0.5× 258 9.3k
Maureen M. Jonas 6.6k 0.8× 7.2k 0.9× 716 0.6× 697 0.9× 238 0.6× 127 8.2k

Countries citing papers authored by Kosh Agarwal

Since Specialization
Citations

This map shows the geographic impact of Kosh Agarwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kosh Agarwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kosh Agarwal more than expected).

Fields of papers citing papers by Kosh Agarwal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kosh Agarwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kosh Agarwal. The network helps show where Kosh Agarwal may publish in the future.

Co-authorship network of co-authors of Kosh Agarwal

This figure shows the co-authorship network connecting the top 25 collaborators of Kosh Agarwal. A scholar is included among the top collaborators of Kosh Agarwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kosh Agarwal. Kosh Agarwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Veloz, María Fernanda Guerra, et al.. (2024). Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma. JHEP Reports. 6(11). 101093–101093.
2.
Tak, Won Young, Wan‐Long Chuang, Chi-Yi Chen, et al.. (2024). Phase Ib/IIa randomized study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB. Journal of Hepatology. 81(6). 949–959. 17 indexed citations
3.
Agarwal, Kosh, Marı́a Buti, Florian van Bömmel, et al.. (2024). JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2. Journal of Hepatology. 81(3). 404–414. 22 indexed citations
4.
Carey, Ivana, et al.. (2022). Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi‐ethnic population: Universal screening is more comprehensive. Journal of Viral Hepatitis. 29(12). 1079–1088. 5 indexed citations
5.
Lim, Young‐Suk, Wai‐Kay Seto, Masayuki Kurosaki, et al.. (2022). Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data. Alimentary Pharmacology & Therapeutics. 55(8). 921–943. 19 indexed citations
6.
Agarwal, Kosh, Jia Xu, Edward Gane, et al.. (2022). Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study. Journal of Viral Hepatitis. 30(3). 209–222. 4 indexed citations
7.
Karvellas, Constantine, Albert Salehi, Jaime L. Speiser, et al.. (2020). O9 Redefining poor prognostic criteria for acetaminophen-induced acute liver failure using regeneration and cell-death linked miRNA signatures. Abstracts. A5.1–A5. 1 indexed citations
8.
Bestwick, Jonathan P., William Gelson, Kosh Agarwal, et al.. (2020). English hepatitis C registry data show high response rates to directly acting anti‐virals, even if treatment is not completed. Alimentary Pharmacology & Therapeutics. 52(1). 168–181. 8 indexed citations
9.
Ajaz, Saima, Mark McPhail, Luigi Gnudi, et al.. (2020). Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion. 57. 119–130. 58 indexed citations
10.
Nayagam, Jeremy, et al.. (2020). The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B. Current Hepatology Reports. 19(4). 362–369. 10 indexed citations
11.
12.
Kemos, Polychronis, Clifford Leen, Adam Lawson, et al.. (2019). The association between hepatocellular carcinoma and direct‐acting anti‐viral treatment in patients with decompensated cirrhosis. Alimentary Pharmacology & Therapeutics. 50(2). 204–214. 18 indexed citations
13.
Younossi, Zobair M., Maria Stepanova, Issah Younossi, et al.. (2019). Patient‐reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. Liver International. 39(10). 1837–1844. 22 indexed citations
14.
Podlaha, Ondřej, Edward Gane, Maurizia Rossana Brunetto, et al.. (2019). Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. Scientific Reports. 9(1). 10529–10529. 15 indexed citations
15.
Carey, Ivana, M. Horner, Matthew Bruce, et al.. (2018). Serum NGAL can act as an early renal safety biomarker during long‐term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B. Journal of Viral Hepatitis. 25(10). 1139–1150. 2 indexed citations
16.
Wang, Bo, et al.. (2018). HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg‐positive patients treated with nucleos(t)ide analogues. Journal of Viral Hepatitis. 25(8). 886–893. 35 indexed citations
17.
Gimson, Alexander, Kosh Agarwal, Mark Aldersley, et al.. (2018). Liver transplant listing for hepatitis C‐associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct‐acting antiviral therapy. Journal of Viral Hepatitis. 26(2). 231–235. 18 indexed citations
18.
Agarwal, Kosh, Sang Hoon Ahn, Audrey Lau, et al.. (2018). Safety and efficacy of vesatolimod (GS‐9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. Journal of Viral Hepatitis. 25(11). 1331–1340. 71 indexed citations
19.
Miller, Michael H., Kosh Agarwal, Ashley Brown, et al.. (2014). Review article: 2014 UK consensus guidelines – hepatitis C management and direct‐acting anti‐viral therapy. Alimentary Pharmacology & Therapeutics. 39(12). 1363–1375. 31 indexed citations
20.
Joshi, Deepak, Ivana Carey, & Kosh Agarwal. (2013). Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. Alimentary Pharmacology & Therapeutics. 37(7). 659–671. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pietro Andreoné Breakdown of academic impact, for papers by Paul J. Pockros Breakdown of academic impact, for papers by Marion G. Peters Breakdown of academic impact, for papers by Robert P. Perrillo Breakdown of academic impact, for papers by Ramsey Cheung Breakdown of academic impact, for papers by Vinod K. Rustgi Breakdown of academic impact, for papers by Lennox J. Jeffers Breakdown of academic impact, for papers by Wan‐Long Chuang Breakdown of academic impact, for papers by Douglas T. Dieterich Breakdown of academic impact, for papers by Maureen M. Jonas
Rankless by CCL
2026